MedTrace Logo

Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery

NCT04029467 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-02-23

No results posted yet for this study

Summary

Patients undergoing Partial or total mastectomy with axillary LN dissection will receive prior to induction of general anaesthesia ESP block at T4 level at the same side of the surgery. one group will receive ropivacaine 0.375% and the other will get ropivacaine 0.375% with dexmedetomidine 0.5mcg/kg as an adjuvant. time to first narcotic requirement will be documented and therefore an assessment of the duration of action of the block will be made

Conditions

  • Breast Cancer
  • Mastectomy
  • Axillary Lymph Node Dissection
  • Pain, Postoperative

Interventions

DRUG

Dexmedetomidine

addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action

Sponsors & Collaborators

  • Lebanese American University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2021-07-17
Completion
2022-01-17
FDA Drug
Yes

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029467 on ClinicalTrials.gov